摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-甲基-1H-苯并咪唑-5-羧酸 | 53484-17-6

中文名称
1-甲基-1H-苯并咪唑-5-羧酸
中文别名
1-甲基苯并咪唑-5-甲酸
英文名称
1-methyl-1H-benzimidazole-5-carboxylic acid
英文别名
1-methylbenzimidazole-5-carboxylic acid
1-甲基-1H-苯并咪唑-5-羧酸化学式
CAS
53484-17-6
化学式
C9H8N2O2
mdl
MFCD06809665
分子量
176.175
InChiKey
KAJLCBKTWRUQOI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    >300(dec.)
  • 沸点:
    411.1±37.0 °C(Predicted)
  • 密度:
    1.35±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.111
  • 拓扑面积:
    55.1
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335
  • 储存条件:
    室温且干燥环境下使用。

SDS

SDS:e022b2987f571baf0d1f0fb58fabbec8
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 1-Methylbenzodiazole-5-carboxylic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 1-Methylbenzodiazole-5-carboxylic acid
CAS number: 53484-17-6

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H8N2O2
Molecular weight: 176.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Synthesis and Evaluation of 5-Fluoro-2-aryloxazolo[5,4-b]pyridines as β-Amyloid PET Ligands and Identification of MK-3328
    摘要:
    5-Fluoro-2-aryloxazolo[5,4-b]pyridines were synthesized and investigated as potential F-18 containing beta-amyloid PET ligands. In competition binding assays using human AD brain homogenates, compounds 14b, 16b, and 17b were identified as having favorable potency versus human beta-amyloid plaque and were radiolabeled for further evaluation in in vitro binding and in vivo PET imaging experiments. These studies led to the identification of 17b (MK-3328) as a candidate PET ligand for the clinical assessment of beta-amyloid plaque load.
    DOI:
    10.1021/ml200018n
  • 作为产物:
    描述:
    4-氯-3-硝基苯甲酸 在 palladium on activated charcoal 、 氢气 作用下, 以 甲醇 为溶剂, 反应 62.0h, 生成 1-甲基-1H-苯并咪唑-5-羧酸
    参考文献:
    名称:
    [EN] NOVEL ARYLALKENE DERIVATIVES AND USE THEREOF AS SELECTIVE ESTROGEN RECEPTOR MODULATORS
    [FR] NOUVEAUX DÉRIVÉS D'ARYLALCÈNE ET UTILISATION DE CEUX-CI EN TANT QUE MODULATEURS SÉLECTIFS DE RÉCEPTEUR D'OESTROGÈNE
    摘要:
    该发明提供了一种新型的乙烯衍生物,其化学式为I,可用作选择性雌激素受体调节剂(SERMs),并在预防和/或治疗依赖雌激素的疾病或症状方面具有用处。
    公开号:
    WO2013097773A1
点击查看最新优质反应信息

文献信息

  • [EN] CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME<br/>[FR] COMPOSÉS DE SULFAMIDE CYCLIQUE ET LEURS PROCÉDÉS D'UTILISATION
    申请人:ASSEMBLY BIOSCIENCES INC
    公开号:WO2018160878A1
    公开(公告)日:2018-09-07
    The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.
    本公开提供了部分环磺胺化合物及其药物组合物,可用作乙型肝炎(HBV)核心蛋白的调节剂,并用于治疗乙型肝炎(HBV)感染的方法。
  • Uniting Amide Synthesis and Activation by P<sup>III</sup>/P<sup>V</sup>–Catalyzed Serial Condensation: Three-Component Assembly of 2-Amidopyridines
    作者:Jeffrey M. Lipshultz、Alexander T. Radosevich
    DOI:10.1021/jacs.1c07608
    日期:2021.9.15
    An organophosphorus (PIII/PV redox) catalyzed method for the three-component condensation of amines, carboxylic acids, and pyridine N-oxides to generate 2-amidopyridines via serial dehydration is reported. Whereas amide synthesis and functionalization usually occur under divergent reaction conditions, here a phosphetane catalyst (together with a mild bromenium oxidant and terminal hydrosilane reductant)
    报道了一种有机磷(P III /P V氧化还原)催化胺、羧酸和吡啶N-氧化物三组分缩合通过连续脱水生成 2-氨基吡啶的方法。虽然酰胺合成和官能化通常发生在不同的反应条件下,但此处显示膦烷催化剂(与温和的溴氧化剂和末端氢硅烷还原剂一起)在自动串联催化级联中以化学选择性驱动这两个步骤。在单一有机催化活性中间体的作用下制备和官能化酰胺的能力为高效和模块化制备药物靶标提供了新的可能性。
  • [EN] N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS D'ACIDES AMINÉS N-ACYLE ET MÉTHODES D'UTILISATION
    申请人:PLIANT THERAPEUTICS INC
    公开号:WO2018049068A1
    公开(公告)日:2018-03-15
    The invention relates to compounds of formula (I), or a salt thereof wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ανβ1 integrin inhibitors that are useful for treating tissue specific fibrosis.
    该发明涉及式(I)的化合物或其盐,其中R1、A、L、R2和n如本文所述。式(I)的化合物及其药物组成物是ανβ1整合素抑制剂,可用于治疗特定组织纤维化。
  • [EN] 2-(4-ARYL-1H-IMIDAZOL-1-YL)ANILINE COMPOUNDS<br/>[FR] COMPOSÉS 2-(4-ARYL-1H-IMIDAZOL-1-YL)ANILINE
    申请人:UNIV COLORADO REGENTS
    公开号:WO2015171951A1
    公开(公告)日:2015-11-12
    The present invention provides compounds that are useful as vaccine adjuvants and/or antitumor agents and methods for producing and using the same. In one particular aspect of the invention, compounds of the invention are of the formula (I) where R1, R2, R3 and Ar1 are those defined herein.
    本发明提供了作为疫苗佐剂和/或抗肿瘤药物有用的化合物,以及制备和使用这些化合物的方法。在本发明的一个特定方面,本发明的化合物具有以下式(I)的结构,其中R1、R2、R3和Ar1如本文所定义。
  • N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors
    申请人:BAGLEY SCOTT WILLIAM
    公开号:US20110111046A1
    公开(公告)日:2011-05-12
    The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R 1 , R 2 , R 3 and R 4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    该发明提供了化合物I的化合物或其药用可接受的盐,其中R1、R2、R3和R4如本文所述;以及其药物组合物;以及在治疗受乙酰辅酶A羧化酶抑制调节的动物疾病、症状或紊乱中的使用。
查看更多